Journal article icon

Journal article

Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK

Abstract:

Summary: The venous thromboembolism risk among anti-osteoporotics is unknown. In this primary care study, the risk with other bisphosphonates [1.05 (0.94–1.18) and 0.96 (0.78–1.18)], strontium [0.90 (0.61–1.34) and 1.19 (0.82–1.74)], in the UK and Spain respectively, and denosumab [1.77 (0.25–12.66)] and teriparatide [1.27 (0.59–2.71)] in Spain, did not differ versus alendronate.

Introduction: Most of the known adverse drug reactions described for anti-osteoporosis medication (AOM)...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1007/s00198-017-4308-5

Authors


More by this author
Role:
Author
ORCID:
0000-0002-3576-8605
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Role:
Author
ORCID:
0000-0002-7034-6168
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Role:
Author
Expand authors...
Publisher:
Springer Verlag Publisher's website
Journal:
Osteoporosis International Journal website
Volume:
29
Issue:
2
Pages:
467-478
Publication date:
2017-12-03
Acceptance date:
2017-11-06
DOI:
EISSN:
1433-2965
ISSN:
0937-941X
Pmid:
29199359
Source identifiers:
809230
Language:
English
Keywords:
Pubs id:
pubs:809230
UUID:
uuid:29f0bf86-f1b6-40dc-af9b-43292de30a8f
Local pid:
pubs:809230
Deposit date:
2018-01-03

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP